Oncternal Therapeutics, Inc. GTXI Income Statement

Oncternal therapeutics, inc. (GTXI)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Grant revenue
578	737	544	674	470	-	329	1,527	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,296	935
Product sales, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	960	599
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8,066	336	336
Operating expenses:
Cost of product sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	216	134
Research and development
2,696	2,568	3,108	2,587	1,896	3,240	1,809	3,513	11,000	6,912	5,914	4,448	4,193	4,585	4,614	4,058	3,971	3,879	3,824	2,956	2,948	3,254	3,362	7,894	6,360	6,088	6,477	10,139	9,614	10,051	9,764	9,237	9,835	8,863	8,181	7,591	7,303	5,593	9,477
In-process research and development
-	-	-	18,088	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
2,633	2,350	2,385	1,619	932	2,346	454	555	2,688	2,487	2,617	1,997	2,087	2,279	2,313	1,999	2,114	2,079	2,039	2,005	2,111	2,203	1,594	3,052	2,629	3,091	2,483	2,684	3,023	2,858	2,999	2,400	2,588	3,141	2,708	2,977	3,201	-	-
Total operating expenses
5,329	4,918	5,493	22,294	2,828	5,586	2,263	4,068	13,688	9,399	8,531	6,445	6,280	6,864	6,927	6,057	6,085	5,958	5,863	4,961	5,059	5,457	4,956	10,946	8,989	9,179	8,960	12,823	12,637	12,909	12,763	11,637	12,423	12,004	10,889	10,568	10,504	-	-
General and administrative expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,066	4,325
Total costs and expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,875	13,936
Loss from operations
-4,751	-4,181	-4,949	-21,620	-2,358	-5,586	-1,934	-2,541	-13,688	-9,399	-8,531	-6,445	-6,280	-6,864	-6,927	-6,057	-6,085	-5,958	-5,863	-4,961	-5,059	-5,457	-4,956	-10,946	-8,989	-9,179	-8,960	-12,823	-12,637	-12,909	-12,763	-11,637	-12,423	-12,004	-10,889	-10,568	-2,438	-8,579	-13,001
Other income:
Change in fair value of warrant liability
-	0	0	1,285	-17	-	-23	-114	-	-	-	-	-	0	0	0	-8,163	-2,729	-40,720	43,016	-2,648	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
13	25	57	59	47	-	13	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income
13	25	57	-1,226	64	171	36	129	131	122	27	40	27	0	13	5	28	-4	9	25	27	-284	21	2	2	1,389	23	21	55	-33	-47	53	8	66	23	7	302	4	60
Income from discontinued operations before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-76	20,214	1,203	1,335	1,256	1,522	-112	-459	-	-
Income tax expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30	8,115	355	381	298	271	264	53	-	-
Net income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-46	12,099	848	954	958	1,251	-376	-512	-	-
Net loss
-4,738	-4,156	-4,892	-22,846	-2,294	-5,415	-1,898	-2,412	-13,557	-9,277	-8,504	-6,405	-6,253	-6,864	-6,914	-6,052	2,106	-3,233	34,866	-47,952	-2,384	-14,545	-4,935	-10,944	-8,987	-7,790	-8,937	-12,802	-12,582	-10,715	5,101	-10,381	-11,080	-10,682	-9,344	-10,673	-2,595	-8,575	-12,941
Loss from operations before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,942	-12,810	-11,584	-12,415	-11,938	-10,866	-10,561	-2,136	-	-
Income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,273	-5,812	-355	-381	-298	-271	-264	-53	-	-
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,669	-6,998	-11,229	-12,034	-11,640	-10,595	-10,297	-2,083	-	-
Basic (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.44	-0.49	-0.43	0.15	-0.23	2.48	-3.42	-0.17	-	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.44	-0.49	-0.43	0.15	-0.40	-0.38	-3.42	-0.17	-	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.17	-0.11	-0.18	-0.19	-0.19	-0.17	-0.20	-0.04	-	-
Net income from discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.19	0.01	0.01	0.02	0.02	-0.01	-0.01	-	-
Net loss per share, basic and diluted
-0.31	1.01	-0.32	-3.38	-0.62	-0.23	-0.53	-0.68	-0.62	-0.43	-0.53	-0.40	-0.39	-	-	-	-	-	-	-	-	-	-	-0.15	-0.14	-	-0.14	-0.20	-0.20	-0.17	0.08	-0.17	-0.18	-0.17	-0.15	-0.21	-0.05	-0.24	-0.36
Basic (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	15,713	14,189	14,174	14,152	14,037	14,037	14,037	14,033	-	76,014	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	15,713	14,189	14,174	14,344	14,952	15,485	14,037	14,033	-	76,014	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average shares outstanding, basic and diluted
15	15	15	6	3	24,051	3	3	21,967	21,541	16,115	16,041	16,018	-	-	-	-	-	-	-	-	-	-	75,433	66,512	-	63,179	62,994	62,864	62,817	62,815	62,805	62,798	62,790	62,778	51,968	51,719	-	-
Basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36,424	36,420,901